Building on solid FY 2023 results, Ipsen anticipates four launches in 2024
IPSEN SA S/ADR (IPSEY)
NASDAQ:AMEX Investor Relations:
ipsen.com/investors
Company Research
Source: GlobeNewswire
Total-sales growth in FY 2023 of 6.7% at CER1 (3.4% as reported) included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS operating margin of 26.1%), based on further enrichment of the pipeline and accelerated R&D investment, mainly from recent acquisitionsFinancial guidance for 20243 comprises total-sales growth4 greater than 6.0% at CER1 and a core operating margin5 around 30% of total sales, including the impact of four potential launches and an advancing pipelineA new phase of growth and mid-term financial outlook were outlined at the December 2023 capital-markets day PARIS, FRANCE, 8 February 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its financial results for the year and final quarter of 2023. Extract of consolidated results for FY 2023 and FY 20226: FY 2023 FY 2022 % change €m €m Actual CER1
Show less
Read more
Impact Snapshot
Event Time:
IPSEY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IPSEY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IPSEY alerts
High impacting IPSEN SA S/ADR news events
Weekly update
A roundup of the hottest topics
IPSEY
News
- Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidanceGlobeNewswire
- Ipsen en Skyhawk Therapeutics kondigen samenwerking aan op het gebied van onderzoek naar RNA-targeting bij zeldzame neurologische aandoeningenPR Newswire
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesPR Newswire
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesPR Newswire
- Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseasesGlobeNewswire